The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Abbott Laboratories (NYSE:ABT), Sarepta Therapeutics (NASDAQ:SRPT).
The investment seeks long-term growth of capital.
The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
The average market capitalization across the Janus Henderson Global Life Sciences D MF is 192.2B. The market cap for tickers in the group ranges from 7.73B to 561.54B. LLY holds the highest valuation in this group at 561.54B. The lowest valued company is SRPT at 7.73B.
The average weekly volume growth across all stocks in the Janus Henderson Global Life Sciences D MF was 3%. For the same stocks of the MF, the average monthly volume growth was -8% and the average quarterly volume growth was 2%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 44
P/E Growth Rating: 48
Price Growth Rating: 47
SMR Rating: 52
Profit Risk Rating: 32
Seasonality Score: 4 (-100 ... +100)